These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26625312)

  • 1. Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
    Pécuchet N; Laurent-Puig P; Mansuet-Lupo A; Legras A; Alifano M; Pallier K; Didelot A; Gibault L; Danel C; Just PA; Riquet M; Le Pimpec-Barthes F; Damotte D; Fabre E; Blons H
    Oncotarget; 2017 Apr; 8(14):23831-23840. PubMed ID: 26625312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Oudart JB; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.
    Zheng J; Deng Y; Huang B; Chen X
    Front Immunol; 2024; 15():1387896. PubMed ID: 38736875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico A; De Giglio A; Parisi C; Gelsomino F
    Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
    Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung Cancer.
    Principe DR; Pasquinelli MM; Nguyen RH; Munshi HG; Hulbert A; Aissa AF; Weinberg F
    Cancer Res Commun; 2024 Aug; 4(8):2282-2294. PubMed ID: 39113608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
    Rosellini P; Amintas S; Caumont C; Veillon R; Galland-Girodet S; Cuguillière A; Nguyen L; Domblides C; Gouverneur A; Merlio JP; Bezin J; Girodet PO
    Eur J Cancer; 2022 Sep; 172():85-95. PubMed ID: 35759814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
    Xu K; Lu W; Yu A; Wu H; He J
    BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Papillon-Cavanagh S; Doshi P; Dobrin R; Szustakowski J; Walsh AM
    ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32312757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
    Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
    Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world.
    Shire NJ; Klein AB; Golozar A; Collins JM; Fraeman KH; Nordstrom BL; McEwen R; Hembrough T; Rizvi NA
    PLoS One; 2020; 15(9):e0238358. PubMed ID: 32881920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Therapeutic Implications of STK11 Mutation: Case Series.
    Laderian B; Mundi P; Fojo T; E Bates S
    Oncologist; 2020 Sep; 25(9):733-737. PubMed ID: 32396674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of
    Bange E; Marmarelis ME; Hwang WT; Yang YX; Thompson JC; Rosenbaum J; Bauml JM; Ciunci C; Alley EW; Cohen RB; Langer CJ; Carpenter E; Aggarwal C
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31428721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional
    Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD
    Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
    Chen L; Engel BE; Welsh EA; Yoder SJ; Brantley SG; Chen DT; Beg AA; Cao C; Kaye FJ; Haura EB; Schabath MB; Cress WD
    J Thorac Oncol; 2016 Jun; 11(6):838-49. PubMed ID: 26917230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.